論文 - 詳細
| RRC ID | 62883 |
|---|---|
| 著者 | Takashima Y, Hamano M, Fukai J, Iwadate Y, Kajiwara K, Kobayashi T, Hondoh H, Yamanaka R. |
| タイトル | GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL. |
| ジャーナル | Sci Rep |
| Abstract |
Primary central nervous system lymphoma (PCNSL) is a brain malignant non-Hodgkin's B-cell lymphoma. The standard treatments are high-dose methotrexate (MTX)-based chemotherapies and deferred whole brain radiotherapy. However, MTX resistance-dependent global expression and signaling pathway changes and their relationship with prognoses have not yet been elucidated. Here, we conducted a global expression analysis with next-generation sequencing and gene set enrichment analysis (GSEA) in MTX-resistant PCNSL cell lines (HKBML-MTX and TK-MTX) and PCNSL tissues. In rank scores, genes listed in HKBML-MTX and TK-MTX were enriched in PCNSL with poor prognoses. In fold changes, a part of differentially-expressed genes in PCNSL tissues were also detected in HKBML-MTX and TK-MTX cells; FOXD2-AS1 and MMP19 were commonly expressed in both HKBML-MTX and TK-MTX, FABP5 and CD70 were HKBML-MTX-specifically expressed, and CLCN2, HOXB9, INE1, and LRP5L were TK-MTX-specifically expressed, which may provide a combination of prognostic markers on MTX-sensitivities in PCNSL. Additionally, PCNSL subgroups, divided with hierarchical clustering and Kaplan-Meier methods, included twenty commonly expressed genes in both HKBML-MTX and TK-MTX, ten HKBML-MTX-specifically expressed genes, and two TK-MTX-specifically expressed genes. These results suggest that the GSEA-assisted gene signatures can provide a combination for prognostic markers in recurrent PCNSL with MTX resistances. |
| 巻・号 | 10(1) |
| ページ | 8435 |
| 公開日 | 2020-5-21 |
| DOI | 10.1038/s41598-020-65463-6 |
| PII | 10.1038/s41598-020-65463-6 |
| PMID | 32439996 |
| PMC | PMC7242340 |
| MeSH | Antimetabolites, Antineoplastic / pharmacology* Apoptosis Biomarkers, Tumor / genetics* Cell Proliferation Central Nervous System Neoplasms / drug therapy Central Nervous System Neoplasms / genetics Central Nervous System Neoplasms / pathology* Drug Resistance, Neoplasm / genetics* Gene Expression Regulation, Neoplastic Humans Lymphoma, Non-Hodgkin / drug therapy Lymphoma, Non-Hodgkin / genetics Lymphoma, Non-Hodgkin / pathology* Methotrexate / pharmacology* Prognosis Tumor Cells, Cultured |
| IF | 3.998 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | X(Twitter) |
| 各媒体での言及数の合計 | 2 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | HKBML(RCB0820) |